Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485

Dow Jones

Jun 25, 2025

By Colin Kellaher

Kymera Therapeutics said Sanofi has pulled the plug on the most advanced drug candidate in the companies' partnership aimed at immune-inflammatory diseases but plans to advance a second candidate into clinical studies.

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

The Watertown, Mass., clinical-stage biotechnology company, said the collaboration will now prioritize KT-485, which Sanofi expects to advance into Phase 1 testing next year.

Kymera said it achieved a $20 million milestone in the second quarter related to preclinical activities associated with KT-485, and that it is eligible to receive up to $975 million of potential clinical, regulatory and commercial milestones related to the drug.

Kymera unveiled its collaboration with France's Sanofi in 2020. At the time, the company received a $150 million upfront payment and said it was eligible for more than $2 billion in potential milestone payments.

Shares of Kymera, which separately on Wednesday announced a cancer-drug option and licensing agreement with Gilead Sciences, were recently down 4.6% in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

June 25, 2025 08:46 ET (12:46 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2546210767"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546210767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546210767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-25 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546210767","market":"other","top_or_hot":-1,"title":"Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> has pulled the plug on the most advanced drug candidate in the companies' partnership aimed at immune-inflammatory diseases but plans to advance a second candidate into clinical studies. \n</p>\n<p>\n  Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the  inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis. \n</p>\n<p>\n  The Watertown, Mass., clinical-stage biotechnology company, said the collaboration will now prioritize KT-485, which Sanofi expects to advance into Phase 1 testing next year. \n</p>\n<p>\n  Kymera said it achieved a $20 million milestone in the second quarter related to preclinical activities associated with KT-485, and that it is eligible to receive up to $975 million of potential clinical, regulatory and commercial milestones related to the drug. \n</p>\n<p>\n  Kymera unveiled its collaboration with France's Sanofi in 2020. At the time, the company received a $150 million upfront payment and said it was eligible for more than $2 billion in potential milestone payments. \n</p>\n<p>\n  Shares of Kymera, which separately on Wednesday announced a cancer-drug option and licensing agreement with Gilead Sciences, were recently down 4.6% in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2025 08:46 ET (12:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKymera: Sanofi Ends KT-474 Work, Will Advance KT-485\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-25 20:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> has pulled the plug on the most advanced drug candidate in the companies' partnership aimed at immune-inflammatory diseases but plans to advance a second candidate into clinical studies. \n</p>\n<p>\n  Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the  inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis. \n</p>\n<p>\n  The Watertown, Mass., clinical-stage biotechnology company, said the collaboration will now prioritize KT-485, which Sanofi expects to advance into Phase 1 testing next year. \n</p>\n<p>\n  Kymera said it achieved a $20 million milestone in the second quarter related to preclinical activities associated with KT-485, and that it is eligible to receive up to $975 million of potential clinical, regulatory and commercial milestones related to the drug. \n</p>\n<p>\n  Kymera unveiled its collaboration with France's Sanofi in 2020. At the time, the company received a $150 million upfront payment and said it was eligible for more than $2 billion in potential milestone payments. \n</p>\n<p>\n  Shares of Kymera, which separately on Wednesday announced a cancer-drug option and licensing agreement with Gilead Sciences, were recently down 4.6% in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2025 08:46 ET (12:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4115","symbol_name":"综合电信业务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2546210767","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546210767","pubTimestamp":1750855560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Kymera Therapeutics said Sanofi has pulled the plug on the most advanced drug candidate in the companies' partnership aimed at immune-inflammatory diseases but plans to advance a second candidate into clinical studies.Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the  inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.The Watertown, Mass., clinical-stage biotechnology company, said the collaboration will now prioritize KT-485, which Sanofi expects to advance into Phase 1 testing next year.Kymera said it achieved a $20 million milestone in the second quarter related to preclinical activities associated with KT-485, and that it is eligible to receive up to $975 million of potential clinical, regulatory and commercial milestones related to the drug.Kymera unveiled its collaboration with France's Sanofi in 2020. At the time, the company received a $150 million upfront payment and said it was e","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4115":"综合电信业务","BK4139":"生物科技","KT":"韩国电信","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNY":"赛诺菲安万特","LU0541502299.USD":"ALLSPRING  EMERGING MARKETS EQUITY \"I\" (USD) ACC","BK4007":"制药","LU0541501648.USD":"ALLSPRING  EMERGING MARKETS EQUITY \"A\" (USD) ACC","KYMR":"Kymera Therapeutics, Inc.","SNYNF":"Sanofi","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"Kymera：赛诺菲结束KT-474工作，将推进KT-485","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"KT":1,"SNY":0.9,"KYMR":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Kymera Therapeutics said Sanofi has pulled the plug on the most advanced drug candidate in the companies' partnership aimed at immune-inflammatory diseases but plans to advance a second candidate into clinical studies. \n\n\n  Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the  inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis. \n\n\n  The Watertown, Mass., clinical-stage biotechnology company, said the collaboration will now prioritize KT-485, which Sanofi expects to advance into Phase 1 testing next year. \n\n\n  Kymera said it achieved a $20 million milestone in the second quarter related to preclinical activities associated with KT-485, and that it is eligible to receive up to $975 million of potential clinical, regulatory and commercial milestones related to the drug. \n\n\n  Kymera unveiled its collaboration with France's Sanofi in 2020. At the time, the company received a $150 million upfront payment and said it was eligible for more than $2 billion in potential milestone payments. \n\n\n  Shares of Kymera, which separately on Wednesday announced a cancer-drug option and licensing agreement with Gilead Sciences, were recently down 4.6% in premarket trading. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 25, 2025 08:46 ET (12:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}